Free Trial

Instil Bio Q2 2024 Earnings Report

Instil Bio logo
$20.97 -0.45 (-2.10%)
As of 01/17/2025 04:00 PM Eastern

Instil Bio EPS Results

Actual EPS
-$2.29
Consensus EPS
-$2.98
Beat/Miss
Beat by +$0.69
One Year Ago EPS
N/A

Instil Bio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Instil Bio Announcement Details

Quarter
Q2 2024
Time
TAS

Conference Call Resources

Instil Bio Earnings Headlines

Instil Bio upgraded to Buy from Hold at Jefferies
The #1 Crypto for AI
We’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-up before it’s too late. It’s urgent because it’s what we consider “The #1 Crypto for the AI World.”
Jefferies Upgrades Instil Bio (TIL)
Instil Bio Secures Loan to Refinance Facility
See More Instil Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Instil Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Instil Bio and other key companies, straight to your email.

About Instil Bio

Instil Bio (NASDAQ:TIL), a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. The company develops cell therapy of tumor infiltrating lymphocyte (TIL) for the treatment of cancer. It is developing early-stage pipeline of CoStAR-TIL and other novel TIL technologies. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.

View Instil Bio Profile

More Earnings Resources from MarketBeat